Journal: BMC Cancer

Article Title: Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models

doi: 10.1186/s12885-026-16153-5

Figure Lengend Snippet: Inhibition of tube formation by combination of fruquintinib plus TAS-102 or bevacizumab plus TAS-102 in HUVECs and HDLECs. A , B Single agent. C - E Combination. HUVECs ( A , C ) and HDLECs ( B , D ) were cultured in basal medium overnight and seeded into µ-plate coated with Geltrex LDEV-Free Reduced Growth Factor Basement Membrane Matrix. The cells were treated with VEGF mixture and various concentrations of fruquintinib, bevacizumab, regorafenib or FTD for 18 h, followed by staining with Calcein AM. Fluorescence image was taken to analyze the tube length. Representative images of tube formation in the combination study in HUVECs and HDLECs were shown ( E ). Data are presented as mean ± standard error ( n = 4). For single agent assays, ** p < 0.01 vs. VEGF (+) control group by Dunnett’s test. # p < 0.05, ## p < 0.01 vs. VEGF (–) control group by Student’s t-test. For combination assays, different alphabet letters indicate significant differences by Tukey-Kramer test, p < 0.05. FTD, trifluridine; HDLEC, human dermal lymphatic endothelial cell; HUVEC, human umbilical vein endothelial cell; VEGF, vascular endothelial growth factor

Article Snippet: For in vitro studies, fruquintinib, bevacizumab, FTD and regorafenib were purchased from MedChemExpress (Monmouth Junction, NJ, USA).

Techniques: Inhibition, Cell Culture, Membrane, Staining, Fluorescence, Control

Journal: BMC Cancer

Article Title: Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models

doi: 10.1186/s12885-026-16153-5

Figure Lengend Snippet: Inhibition of ERK and Akt phosphorylation and induction of Chk1 phosphorylation by combination of fruquintinib or bevacizumab plus FTD in HUVECs and HDLECs. A - E Single agent. F-L Combination. HUVECs ( A , B , C , F , G , H , K ) and HDLECs ( A , D , E , F , I , J , L ) were cultured in basal medium overnight, seeded into 24 well plate coated with Geltrex LDEV-Free Reduced Growth Factor Basement Membrane Matrix. The cells were treated with FTD, fruquintinib, regorafenib or bevacizumab at indicated concentrations for 4 h. Then, the cells were treated with VEGF mixture for 10 min. The cells were lysed and subject to the Simple Western automated western blot system. ( A , B , F , G ) pERK/ERK in HUVECs, ( A , C , F , H ) pAkt/Akt in HUVECs, ( F , K ) pChk1/Chk1 in HUVECs, ( A , D , F , I ) pERK/ERK in HDLECs, ( A , E , F , J ) pAkt/Akt in HDLECs and ( F , L ) pChk1/Chk1 in HDLECs. Full-length blots are presented in Supplementary Fig. 1&2. Akt, protein kinase B; Chk1, checkpoint kinase 1; ERK, extracellular signal-related kinase; FTD, trifluridine; HDLEC, human dermal lymphatic endothelial cell; HUVEC, human umbilical vein endothelial cell; pAkt, phosphorylated protein kinase B; pChk1, phosphorylated checkpoint kinase 1; pERK, phosphorylated extracellular signal-related kinase VEGF, vascular endothelial growth factor

Article Snippet: For in vitro studies, fruquintinib, bevacizumab, FTD and regorafenib were purchased from MedChemExpress (Monmouth Junction, NJ, USA).

Techniques: Inhibition, Phospho-proteomics, Cell Culture, Membrane, Simple Western, Western Blot